Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced the closing of an £8 million extension to its Series A funding…
Read More
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has recruited the first subject in a Phase IIa study…
Read More
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced a £3.3 million collaborative project to progress its new drug, AUT00206 into…
Read More
Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has initiated a Phase IIa study in tinnitus subjects with…
Read More
